Day 4: Top Takeaways From ASCO24
Dr. John Sweetenham shares highlights from Day 4 of the 2024 ASCO Annual Meeting, including exciting new data from the IMROZ trial in multiple myeloma, adjuvant therapy for triple-negative breast cancer in A-BRAVE, and the front-line treatment of advanced renal cell carcinoma in JAVELIN Renal-101.
TRANSCRIPT
Dr. John Sweetenham: I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my top takeaways on selected abstracts from Day 4 of the 2024 ASCO Annual Meeting.
Today's selection features 3 randomized prospective trials in the first-line treatment of multiple myeloma…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.